| 1 |
NCT01099579 |
Completed
Has Results |
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV) |
|
- Drug: Atazanavir powder
- Drug: Ritonavir oral solution
- Drug: Atazanavir capsules
- Drug: Ritonavir capsules
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation
- Number of Participants With Laboratory Test Results With Worst Toxicity of Grade 3-4
- Electrocardiogram Changes From Baseline in PR Interval, QTC Bazett, and QTC Fridericia at Week 48
- (and 15 more...)
|
82 |
All |
3 Months to 66 Months (Child) |
NCT01099579 |
AI424-397
2009-016361-28 |
PRINCE1 |
October 13, 2010 |
October 4, 2012 |
September 11, 2017 |
April 7, 2010 |
January 23, 2018 |
February 6, 2014 |
- Local Institution
Sao Paolo, SAO Paulo, Brazil - Local Institution
Santiago, Metropolitana, Chile - Local Institution
Santiago, Metropolitana, Chile - (and 15 more...)
|
| 2 |
NCT01095224 |
Completed |
Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults |
|
- Biological: rAd35 Env A
- Biological: rAd5 Env A
- Biological: rAd5 Env B
|
Interventional |
Phase 1 |
- National Institute of Allergy and Infectious Diseases (NIAID)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Frequency and severity of local injection site reactogenicity signs and symptoms, including pain, tenderness, erythema, induration, and maximum severity of pain and/or tenderness
- Frequency and severity of systemic reactogenicity signs and symptoms, including fever, malaise/fatigue, myalgia, headache, nausea, vomiting, chills, arthralgia, and maximum severity of systemic symptoms
- Frequency of adverse events (AEs) categorized by MedDRA body system, MedDRA preferred term, severity and assessed relationship to study products; detailed description of all AEs meeting DAIDS criteria for expedited reporting
- (and 9 more...)
|
180 |
All |
18 Years to 50 Years (Adult) |
NCT01095224 |
HVTN 083
10783 |
|
September 2010 |
October 2012 |
February 2016 |
March 30, 2010 |
August 18, 2017 |
|
- Alabama CRS
Birmingham, Alabama, United States - Bridge HIV CRS
San Francisco, California, United States - The Hope Clinic of the Emory Vaccine Center CRS
Decatur, Georgia, United States - (and 5 more...)
|
| 3 |
NCT01095796 |
Completed
Has Results |
Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults |
|
- Drug: Stribild
- Drug: Atripla
- Drug: Stribild Placebo
- Drug: Atripla Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Percentage of Participants With Virologic Success Using the Food and Drug Administration (FDA)-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 Ribonucleic Acid (RNA) < 50 Copies/mL at Week 48
- The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 96
- The Percentage of Participants With Virologic Success Using the FDA-Defined Snapshot Analysis as Determined by the Achievement of HIV-1 RNA < 50 Copies/mL at Week 144
- (and 4 more...)
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT01095796 |
GS-US-236-0102 |
|
March 2010 |
August 2011 |
September 2014 |
March 30, 2010 |
November 11, 2015 |
October 22, 2012 |
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Spectrum Medical Group
Phoenix, Arizona, United States - Health for Life Clinic PLLC
Little Rock, Arkansas, United States - (and 99 more...)
|
| 4 |
NCT01098045 |
Completed |
HIV Fat Redistribution and the Evaluation of Brown Fat |
|
|
Observational |
|
- Massachusetts General Hospital
- Beth Israel Deaconess Medical Center
|
Other |
- Observational Model: Case Control
- Time Perspective: Cross-Sectional
|
- Brown Fat
- UCP-1
- Indirect Calorimetry
- (and 2 more...)
|
27 |
Male |
20 Years to 60 Years (Adult) |
NCT01098045 |
2009P-001836 |
|
March 2010 |
June 2014 |
August 2015 |
April 2, 2010 |
March 16, 2016 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 5 |
NCT01087840 |
Completed |
Raltegravir Use as Nonoccupational Postexposure Prophylaxis (NPEP) in Men Who Have Sex With Men |
- HIV Prevention
- HIV Infections
|
|
Interventional |
Phase 4 |
- Andrew Carr
- Merck Sharp & Dohme Corp.
- St Vincent's Hospital, Sydney
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To describe the safety of 28 days of nonoccupational post-exposure prophylaxis containing raltegravir
- To describe the tolerability of 28 days of NPEP containing raltegravir
- To describe on-drug adherence and regimen completion rates of 28 days of NPEP containing raltegravir
- (and 3 more...)
|
120 |
Male |
18 Years to 70 Years (Adult, Senior) |
NCT01087840 |
RAL-NPEP version 1. |
RAL-NPEP |
July 2010 |
May 2012 |
July 2012 |
March 16, 2010 |
April 17, 2014 |
|
- Sydney Sexual Health, Sydney Hospital
Sydney, New South Wales, Australia - St. Vincent's Hospital, 390 Victoria Rd, Darlinghurst
Sydney, New South Wales, Australia
|
| 6 |
NCT01111721 |
Completed |
Project POWER, Adapting Project SAFE: Reducing STD/HIV Risk in Women Prisoners |
|
- Behavioral: Project POWER HIV Risk-reduction Intervention
- Behavioral: NC DOC Standard of Care for STIs
|
Interventional |
Not Applicable |
- University of North Carolina, Chapel Hill
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- STI Infection Rate
- Number of unprotected sex acts as a measure of enacting sexual protective practices.
|
598 |
Female |
18 Years and older (Adult, Senior) |
NCT01111721 |
09-1433
5UR6PS000670 |
POWER |
March 2009 |
December 2012 |
December 2012 |
April 28, 2010 |
March 14, 2013 |
|
- North Carolina Correctional Institution for Women
Raleigh, North Carolina, United States - Fountain Correctional Center for Women
Rocky Mount, North Carolina, United States
|
| 7 |
NCT01087814 |
Completed
Has Results |
Sustiva Levels With Use of a Gel Capsule |
|
- Drug: Efavirenz
- Drug: Over-encapsulated efavirenz
|
Interventional |
Phase 4 |
- University of Minnesota - Clinical and Translational Science Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Basic Science
|
- Serum Levels of Efavirenz
|
16 |
All |
18 Years and older (Adult, Senior) |
NCT01087814 |
0910M73917 |
|
February 2010 |
September 2010 |
September 2011 |
March 16, 2010 |
March 9, 2017 |
September 12, 2014 |
- University of Minnesota
Minneapolis, Minnesota, United States
|
| 8 |
NCT01092338 |
Completed
Has Results |
Vitamin D Dose Finding Study |
|
- Drug: Cholecalciferol (Vit D3)
|
Interventional |
Phase 2 |
- Children's Hospital of Philadelphia
- National Institutes of Health (NIH)
- National Center for Complementary and Integrative Health (NCCIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Safety
- Efficacy of the Two Doses (4000 and 7000 IU/d)
|
44 |
All |
5 Years to 24 Years (Child, Adult) |
NCT01092338 |
09-007332
R01AT005531 |
|
January 2010 |
January 2011 |
January 2011 |
March 24, 2010 |
September 18, 2013 |
September 18, 2013 |
- Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 9 |
NCT01090648 |
Completed |
TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients |
|
|
Interventional |
Phase 1 |
- Tibotec Pharmaceuticals, Ireland
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
|
- Questionnaire using a 7-point scale to determine the acceptability of swallowing an uncoated 200 mg etravirine (ETR) tablet
|
49 |
All |
18 Years and older (Adult, Senior) |
NCT01090648 |
CR017038 |
|
March 2010 |
May 2010 |
May 2010 |
March 22, 2010 |
December 11, 2012 |
|
|
| 10 |
NCT01101815 |
Recruiting |
Adherence to HIV Therapy in Heroin Addicts |
- HIV
- Substance Abuse
- HIV Infections
|
- Drug: Oral Naltrexone (ON)
- Drug: Implantable Naltrexone (IN)
|
Interventional |
Phase 3 |
- University of Pennsylvania
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adherence Oral (ON) vs Implant (IN) naltrexone
- Compare efficacy of the two treatments on:
|
200 |
All |
18 Years to 64 Years (Adult) |
NCT01101815 |
DA026336
R01DA026336 |
|
June 2011 |
January 2017 |
January 2017 |
April 12, 2010 |
August 19, 2016 |
|
- Leningrad Region Addiction Treatment
Leningrad Region, Russian Federation - Leningrad Region AIDS Center
St. Petersburg, Russian Federation
|
| 11 |
NCT01088295 |
Completed
Has Results |
HIV and Fat Accumulation |
|
|
Interventional |
Phase 2 |
- University of California, Los Angeles
- California HIV/AIDS Research Program
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Median Change in Visceral Adipose Tissue (VAT) Volume
- Safety and Tolerability of Telmisartan
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT01088295 |
MATH |
MATH |
May 2010 |
June 2011 |
June 2011 |
March 17, 2010 |
June 30, 2014 |
February 18, 2013 |
- UCLA CARE Center
Los Angeles, California, United States
|
| 12 |
NCT01102972 |
Completed
Has Results |
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE) |
- Infection, Human Immunodeficiency Virus
|
- Drug: Reyataz + Norvir + Truvada
- Drug: Reyataz + Epzicom
|
Interventional |
Phase 4 |
- ViiV Healthcare
- GlaxoSmithKline
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 Copies (c)/Milliliter (mL) at the Week 24 Visit: TLOVR Analysis
- Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 c/mL at the Week 24 Visit: Observed, M/D=F, and SNAPSHOT Analyses
- Percentage of Participants (PAR) Who Achieved Plasma HIV-1 RNA <50 c/mL at the Week 48 Visit: TLOVR, Observed, M/D=F, and SNAPSHOT Analyses
- (and 20 more...)
|
297 |
All |
18 Years and older (Adult, Senior) |
NCT01102972 |
113734 |
ASSURE |
April 2010 |
June 2012 |
December 2012 |
April 13, 2010 |
November 19, 2013 |
December 31, 2012 |
- GSK Investigational Site
Hobson City, Alabama, United States - GSK Investigational Site
Phoenix, Arizona, United States - GSK Investigational Site
Phoenix, Arizona, United States - (and 43 more...)
|
| 13 |
NCT01090245 |
Completed |
Using Incentives to Improve Parolee Participation and Attendance in Community Treatment |
- Substance Abuse
- HIV Infections
|
- Behavioral: Contingency management: voucher/monetary incentives for treatment attendance
- Behavioral: Information
|
Interventional |
Not Applicable |
- University of California, Los Angeles
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Community treatment admission
- Community treatment retention
- Participation in HIV testing and counseling
- (and 3 more...)
|
202 |
Male |
18 Years and older (Adult, Senior) |
NCT01090245 |
1R01DA025627-01A1 |
PIP |
April 2010 |
January 2014 |
August 2014 |
March 19, 2010 |
May 10, 2017 |
|
|
| 14 |
NCT01098513 |
Completed |
GSK1349572 Relative Bioavailability Study |
- Infection, Human Immunodeficiency Virus
|
- Drug: GSK1349572 formulation AP
- Drug: GSK1349572 formulation AW
- Drug: GSK1349572 formulation AX
|
Interventional |
Phase 1 |
- ViiV Healthcare
- GlaxoSmithKline
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma GSK1349572 AUC(0-infinity), AUC(0-t), and Cmax.
- Plasma GSK1349572 t½, tlag, tmax, C24, Vdss/F, CL/F, and MRT.
- Safety and tolerability parameters, including adverse events, concurrent medication, clinical laboratory screens, ECG, and vital signs assessments.
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT01098513 |
113674 |
|
April 2010 |
June 2010 |
July 2010 |
April 2, 2010 |
June 9, 2017 |
|
- GSK Investigational Site
Austin, Texas, United States
|
| 15 |
NCT01131273 |
Completed |
HIV Risk Reduction in Subutex Injectors in Tbilisi |
|
- Drug: methadone
- Drug: buprenorphine-naloxone (Suboxone) for 12 weeks
|
Interventional |
Phase 3 |
- University of Pennsylvania
- National Institute on Drug Abuse (NIDA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Buprenorphine injecting
- HIV Risk
|
68 |
All |
25 Years to 50 Years (Adult) |
NCT01131273 |
RDA026754A
R21DA026754
DPMC |
|
June 2010 |
August 2013 |
August 2013 |
May 26, 2010 |
August 19, 2016 |
|
- Union Alternative Georgia
Tbilisi, Georgia
|
| 16 |
NCT01093417 |
Completed
Has Results |
Study of Vitamin D and Effect on Heart Disease and Insulin Resistance |
- Human Immunodeficiency Virus (HIV)
- Vitamin D Deficiency
- HIV Infections
|
- Drug: Vitamin D
- Other: Placebo
|
Interventional |
Phase 2 |
- University Hospitals Cleveland Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
|
- Change in Endothelial Function
- Change in Serum 25-hydroxyvitamin D Concentration in Both Groups
|
45 |
All |
18 Years and older (Adult, Senior) |
NCT01093417 |
11-09-30 |
|
January 2010 |
October 2010 |
October 2010 |
March 25, 2010 |
July 14, 2016 |
February 29, 2012 |
- University Hospitals of Cleveland Case Medical Center
Cleveland, Ohio, United States
|
| 17 |
NCT01101893 |
Completed |
A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects |
- Infection, Human Immunodeficiency Virus
|
- Drug: Raltegravir
- Drug: GSK2248761
- Drug: GSK2248761 + Raltegravir
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Plasma raltegravir steady-state CL/F, AUC(0-tau), Cmax, tmax, Ctau, and Cmin following administration of raltegravir 400mg q12h for 5 days and following co-administration with GSK2248761 200mg q24h for 5 days.
- Plasma GSK2248761 steady state PK parameters, including CL/F, AUC(0-tau), Cmax, tmax, Ctau, & Cmin following administration of GSK2248761 200mg q24h for 5 days & following co-administration of raltegravir 400 mg q12h & GSK2248761 200 mg q24h for 5 days
- Safety and tolerability parameters, including adverse event, concurrent medication, clinical laboratory, ECG, and vital signs assessments
|
15 |
All |
18 Years to 50 Years (Adult) |
NCT01101893 |
113392 |
|
April 2010 |
June 2010 |
June 2010 |
April 12, 2010 |
September 11, 2017 |
|
- GSK Investigational Site
Buffalo, New York, United States
|
| 18 |
NCT01089114 |
Completed |
Cardiovascular Radiologic and Metabolic Assessment in HIV: An Investigation of Pathophysiology |
- HIV
- Cardiovascular Disease
|
|
Observational |
|
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
- Intramyocardial triglyceride
|
168 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT01089114 |
100080
10-I-0080 |
|
March 8, 2010 |
|
August 7, 2015 |
March 18, 2010 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 19 |
NCT01137981 |
Recruiting |
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects |
- Infection, Human Immunodeficiency Virus
|
- Drug: Any Antiretroviral Therapy
|
Observational |
|
- ViiV Healthcare
- GlaxoSmithKline
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- A birth defect is defined as any congenital malformations according to modified (by APR) classification of Centers for Disease Control and Prevention (CDC)'s Metropolitan Atlanta Congenital Defects Program (MACDP) criteria
|
1 |
Female |
Child, Adult, Senior |
NCT01137981 |
112885
WE066 (EPIP095)
EPI40018 |
|
February 15, 1993 |
December 31, 2024 |
December 31, 2024 |
June 7, 2010 |
October 24, 2017 |
|
- GSK Investigational Site
Wilmington, North Carolina, United States
|
| 20 |
NCT01125696 |
Unknown † |
Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV |
|
- Drug: Tenofovir/lamivudine/lopinavir-ritonavir
- Drug: Zidovudine/lamivudine/lopinavir-ritonavir
|
Interventional |
Phase 2 |
- Centers for Disease Control and Prevention
- National Center for AIDS/STD Control and Prevention, China CDC
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Tenofovir Safety for mothers measured by incidence of serious adverse events (SAEs)
- Dual Energy X-ray absorptiometry (DXA) scans of bone mineral density
- Maternal Tenofovir Pharmacokinetics
- (and 7 more...)
|
80 |
Female |
20 Years and older (Adult, Senior) |
NCT01125696 |
CDC-NCCDPHP-5877 |
TiP |
May 2012 |
May 2015 |
August 2016 |
May 18, 2010 |
February 3, 2015 |
|
- Liuzhou MCH Hospital
Liuzhou, Guangxi, China - Guangxi MCH Hospital
Nanning, Guangxi, China
|
| 21 |
NCT01097070 |
Completed |
A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days |
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Measure bevirimat blood plasma concentrations to calculate the pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life when bevirimat is administered as 2 x 100 mg tablets BID, 3 X 100 mg tablets QD, 4 X 100 mg tablets QD for 15 days
- Measure bevirimat blood plasma concentrations following the administration of bevirimat 2 X 100 mg, 3 x 100 mg, or 4 x 100 mg tablets after a standardized meal. The pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life will be calculated.
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT01097070 |
Bevirimat Study 206 |
|
November 2008 |
January 2009 |
January 2009 |
April 1, 2010 |
April 1, 2010 |
|
- Quest Clinical Research
San Francisco, California, United States - Gary J. Richmond, MD, PA
Ft. Lauderdale, Florida, United States - AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States - Community Research Initiative of New England
Boston, Massachusetts, United States
|
| 22 |
NCT01092104 |
Completed |
A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients |
|
- Drug: TBR-652
- Drug: TBR-652 Matching Placebo
- Drug: TBR-652 50 mg
- (and 3 more...)
|
Interventional |
Phase 1
Phase 2 |
- Tobira Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- HIV-1 RNA Change from Baseline
|
52 |
All |
18 Years and older (Adult, Senior) |
NCT01092104 |
652-2-201 |
|
February 2009 |
November 2009 |
November 2009 |
March 24, 2010 |
July 10, 2013 |
|
|
| 23 |
NCT01138605 |
Completed |
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV |
|
- Drug: Darunavir
- Drug: Ritonavir
|
Interventional |
Phase 2 |
- Janssen Sciences Ireland UC
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of DRV/rtv in combination with other ARVs will be summarized in terms of Mortality, all Serious Adverse Events,Adverse events leading to discontinuation and Adverse Events at least possibly related to the DRV treatment
|
46 |
All |
3 Years to 99 Years (Child, Adult, Senior) |
NCT01138605 |
CR016768
TMC114-TiDP29-C232
2009-017013-29 |
|
October 13, 2010 |
November 23, 2017 |
November 23, 2017 |
June 7, 2010 |
January 9, 2018 |
|
- Buenos Aires, Argentina
- Ciudad Autonoma Buenos Aires, Argentina
- Ribeirão Preto, Brazil
- (and 10 more...)
|
| 24 |
NCT01086878 |
Completed |
Safety of Cotrimoxazole in HIV- and HAART-exposed Infants |
- Acquired Immunodeficiency Syndrome
- Infant, Newborn
- Anemia
- (and 2 more...)
|
|
Interventional |
Phase 4 |
- Harvard School of Public Health
- National Institute of Allergy and Infectious Diseases (NIAID)
- John E. Fogarty International Center (FIC)
- (and 2 more...)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- incidence of severe or life-threatening anemia
- incidence of severe or life-threatening neutropenia
- composite severe morbidity and mortality
|
222 |
All |
Child, Adult, Senior |
NCT01086878 |
BHP031
2P30AI060354-06
3R24TW007988-01S1 |
|
February 2009 |
October 2010 |
October 2010 |
March 15, 2010 |
February 25, 2011 |
|
- Scottish Livingstone Hospital
Molepolole, Kweneng, Botswana - Princess Marina Hospital
Gaborone, Botswana
|
| 25 |
NCT01090102 |
Completed
Has Results |
Mesalamine to Reduce T Cell Activation in HIV Infection |
- HIV Infections
- Sexually Transmitted Diseases
- Immune System Diseases
- (and 2 more...)
|
- Drug: Mesalamine (5-aminosalicylic acid, Apriso)
- Drug: Placebo
|
Interventional |
Phase 4 |
- University of California, San Francisco
- California HIV/AIDS Research Program
- Valeant Pharmaceuticals International, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells During the First 12 Weeks of Study
- Log(10) Change in % Activated (CD38+HLA-DR+)CD8+ T Cells After Treatment Crossover
|
33 |
All |
18 Years and older (Adult, Senior) |
NCT01090102 |
164320 |
|
June 2010 |
December 2012 |
December 2012 |
March 19, 2010 |
August 13, 2014 |
August 11, 2014 |
- University of California, San Francisco-San Francisco General Hospital
San Francisco, California, United States
|
| 26 |
NCT01092611 |
Completed |
Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine |
|
- Procedure: Blood collection
- Biological: GSK HIV vaccine 732462
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Occurrence of Anti-Retroviral Therapy (ART) (re)-initiation or ART modification, and reason (for ART modification)
- CD4 count
- Viral load (VL) and method of measurement
- (and 14 more...)
|
190 |
All |
18 Years to 55 Years (Adult) |
NCT01092611 |
114083
2009-018097-64 |
|
March 22, 2010 |
March 17, 2014 |
May 19, 2014 |
March 25, 2010 |
March 2, 2018 |
|
- GSK Investigational Site
Bakersfield, California, United States - GSK Investigational Site
Fort Lauderdale, Florida, United States - GSK Investigational Site
Orlando, Florida, United States - (and 38 more...)
|
| 27 |
NCT01092182 |
Active, not recruiting |
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma |
- Burkitt Lymphoma
- Diffuse Large B-cell Lymphoma, c-MYC Positive
- Plasmablastic Lymphoma
|
- Drug: EPOCH-R
- Drug: EPOCH-RR
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
194 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01092182 |
100052
10-C-0052 |
|
February 24, 2010 |
February 28, 2021 |
February 28, 2023 |
March 24, 2010 |
April 5, 2018 |
|
- Mercy Medical Center-Sioux City
Sioux City, Iowa, United States - Saint Luke's Regional Medical Center
Sioux City, Iowa, United States - Siouxland Hematology Oncology Associates LLP
Sioux City, Iowa, United States - (and 29 more...)
|
Create an RSS feed from your search for:
Download the search results for: